Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana Prior Auth and Notification List | OpenPaye…
    Ask Trek AI about this page
    CurrentHumanaPolicy N/A

    H1036-280 Humana Fully Integrated Florida prior authorization and notification list

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medications and related services that require prior authorization or notification for Humana Fully Integrated Florida HMO D-SNP plans and explains how providers should request authorizations; affects participating providers and delegated networks serving Humana MA HMO/HMO POS members in the plan.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerHumana
    PolicyH1036-280 Humana Fully Integrated Florida prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before providing or administering listed medications and follow submission methods (CoverMyMeds, phone 866-461-7273 TTY 711, or fax 888-447-3430).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    manylisted drugs (document)
    3submission methods
    9090-day exception
    866-461-7273prior auth phone
    888-447-3430prior auth fax
    NDC reqNDC billing note

    Prior Authorization and Coverage Criteria

    Prior authorization and coverage criteria

    Covered when ALL of the following are met:

    Medication or service is listed on the H1036-280 prior authorization and notification list (prior authorization required before administration).

    See drug-specific entries for billing codes and flags.

    Service meets Medicare medical necessity guidelines as established by CMS (medical care, services, supplies, and equipment must be medically necessary).

    Refer to CMS coverage guidelines and Humana Medical and Pharmacy Coverage Policies.

    If the drug is designated with a step therapy indicator ('**'), the member has met Humana Part B step therapy requirements (trial of Humana‑preferred drug when required).

    See Humana's Medicare Part B Step Therapy Preferred Drug List for details.

    Investigational or experimental procedures/devices are excluded unless covered under an Evidence of Coverage or other Humana guidance.

    Confirm coverage by consulting the patient's Evidence of Coverage or contacting Humana.

    When a shared HCPCS or not‑otherwise‑classified (NOC) code is used (marked '‡'), a corresponding National Drug Code (NDC) must be billed on the claim.

    This billing requirement applies to codes such as C9399, J3490, J3590, J9999 and other shared HCPCS entries.

    Authorization requests are submitted using approved methods (online via CoverMyMeds where available, phone, or fax); transplant‑related requests follow Humana National Transplant Network routing.

    Provider submission methods and transplant routing details are specified in the PAL.

    Providers should be aware that failure to obtain required prior authorization may result in financial penalties, reduced patient benefits, or retrospective medical necessity review.

    Obtain prior authorization before administration to avoid potential adverse payment consequences.

    Administrative authorization criteria

    Administrative coverage stance and process requirements for listed drugs:

    Drugs on the H1036-280 list require prior authorization or notification as indicated in the list entries.

    Refer to each drug entry for specific preauthorization or notification instructions and required billing codes.

    HCPCS or NOC codes marked with '‡' must include a corresponding NDC on all claims.

    This applies to shared HCPCS and NOC codes throughout the list (see examples in the PAL).

    Drugs marked with '**' are subject to step therapy and require trial of a Humana‑preferred drug as part of preauthorization.

    Review Humana's Part B Step Therapy Preferred Drug List for preferred alternatives and cross‑benefit strategies.

    Entries marked '††' (transplant review) will be routed to the Humana National Transplant Network for review and must be submitted via the transplant contact methods (fax/phone/email).

    Transplant submission fax: 502-508-9300; phone: 866-421-5663; email: transplant@humana.com (Mon–Fri 7 a.m.–7 p.m. CT).

    Prior authorization requirement by drug

    Listed drugs require prior authorization or notification as indicated in the H1036-280 prior authorization and notification list. Examples and flags from the list include:

    Examples of drug entries

    • Soliris (eculizumab) — billing code: J1299; flagged '**' (step therapy).
    • Rybrevant IV (amivantamab-vmjw) — billing code: J9061; example mapping shown in list.
    • Ryplazim (plasminogen, human-tvmh) — billing code: J2998; listed as requiring prior authorization/notification.

    HCPCS, CPT, and Billing Requirements

    Example HCPCS/Q-codes from medication listHCPCS
    J9264Abraxane (paclitaxel-nab) - billed HCPCS
    Q2055Abecma (idecabtagene vicleucel) - billing code
    Additional HCPCS/Q-codesHCPCS
    J1569Gammagard - immune globulin
    Q5130Fylnetra - pegfilgrastim-pbbk
    Representative HCPCS and Q-codes from listHCPCS
    J2506pegfilgrastim (Neulasta) HCPCS
    J1447tbo-filgrastim (Granix) HCPCS
    J1560immune globulin HCPCS (example: GamaSTAN)
    Representative Q/A codesmixed
    Q5130pegfilgrastim-pbbk (Fylnetra) Q-code
    A9513lutetium Lu 177 dotatate (Lutathera) pass-through
    Selected HCPCS/CPT mappings from listHCPCS
    J0596Ruconest (example mapping shown in list)
    J9061Rybrevant IV (example mapping shown in list)
    J1299Soliris (example mapping shown in list)
    Blood-clotting factor HCPCS mappingsHCPCS
    J7192Advate / antihemophilic factor (example)
    J7207Adynovate (example)
    HCPCS-to-NDC billing requirement — shared HCPCS and NOC codes
    RequirementAll shared HCPCS and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on claims.
    ScopeApplies to medications listed with shared HCPCS or C9399/J3490-type NOC codes across the prior authorization list.
    ReasonEnsures identification of the specific drug product when multiple products map to the same HCPCS/NOC code.
    Billing actionSubmit the corresponding NDC on every claim that includes a shared HCPCS or NOC code to avoid claim denial or processing delays.
    NDC billing requirement for shared HCPCS/C9399/J3490-type codes

    How Providers Should Request Authorizations and Required Actions

    Step Therapy

    Step therapy and Part B PDL

    Prior authorization is required for many medications and services listed on the H1036-280 prior authorization and notification list. Providers must follow the Part B Step Therapy and Part B PDL requirements where applicable, and bill per the authorization annotations and billing notes. Failure to obtain required prior authorization may lead to financial penalties, reduced benefits for the member, or retrospective medical necessity review.

    • Step therapy: Some Medicare Part B medications are subject to step therapy; affected medications are noted with a step therapy indicator on the Medicare PAL.
    • Part B PDL: Review Humana's Medicare Part B Step Therapy Preferred Drug List (PDL) on Humana's provider prior authorization notification lists website for preferred/nonpreferred listings and cross-benefit strategies.
    • Coverage policies: Review Humana's Medical and Pharmacy Coverage Policies in conjunction with the Part B PDL for specific criteria and possible exceptions.

    Definitions and Annotation Key

    Prior authorization — definition
    DefinitionPrior authorization (also called preauthorization or precertification) is a process through which the healthcare provider must obtain advance approval from the plan to determine whether an item or service will be covered.
    When requiredThe list details medications delivered in office, clinic, outpatient, or home settings that require prior authorization before being provided or administered.
    StandardsServices must meet CMS Medicare medical necessity guidelines to be covered.
    Advance coverage determination (ACD) — definition and scope
    DefinitionAdvance coverage determination (ACD) is a request to determine in advance if Humana will pay for an investigational, experimental, or limited‑benefit procedure or medication.
    How to request
    Policy Summary
    PayerHumana
    PolicyH1036-280 Humana Fully Integrated Florida prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before providing or administering listed medications and follow submission methods (CoverMyMeds, phone 866-461-7273 TTY 711, or fax 888-447-3430).
    SourceLink
    On This Page
    Prior Authorization and Coverage CriteriaHCPCS, CPT, and Billing RequirementsHow Providers Should Request Authorizations and Required ActionsDefinitions and Annotation Key
    RequirementA corresponding National Drug Code (NDC) must be billed on all claims when shared HCPCS or not otherwise classified codes (e.g., C9399, J3490) are used.
    ExamplesEntries such as Rybrevant Faspro (C9399, J3490) explicitly indicate the NDC billing requirement for those codes.
    ConsequenceFailure to include the NDC may result in claim processing issues; include NDC to identify the exact product supplied.
    Billing Rule

    Authorization annotations and billing notes

    Authorization annotations and billing notes on the prior authorization list indicate special processing or billing requirements. Providers must follow these annotations when submitting requests or claims to avoid denials or claim reprocessing.

    • Legend: * = New preauthorization requirement; † = New-to-market drug addition; ‡ = All shared HCPCS and not otherwise classified codes require a corresponding NDC to be billed on all claims.
    • ** = Step therapy required through a Humana-preferred drug as part of preauthorization.
    • †† = Preauthorization requests for transplant-related items will be reviewed by the Humana National Transplant Network (see transplant routing).
    • Billing co-requirements: For codes annotated with ‡, include the corresponding NDC on all claims; follow Humana Medicare Advantage Payment Policy (CP2023011) for required modifiers when applicable.
    Prior Authorization

    How to request prior authorization (forms)

    How to request prior authorization and access request forms: Prior authorization for medications may be initiated online, by phone, fax, or using Humana’s preauthorization fax forms. For transplant-related preauthorization requests, follow the Humana National Transplant Network routing below.

    • Online: Submit requests via CoverMyMeds (http://www.covermymeds.com/).
    • Phone: 866-461-7273 (TTY: 711), Monday - Friday, 8 a.m. - 11 p.m., Eastern time; for general provider questions call 800-457-4708 (TTY: 711), daily, 8 a.m. - 8 p.m., Eastern time.
    • Fax: 888-447-3430. Request forms are available on Humana's prior authorization for professionally administered drugs webpage; access the H1036-280 fax forms to request preauthorization or provide notification.
    • Transplant preauthorization routing: Requests for transplant-related preauthorizations will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday ─ Friday, 7 a.m. ─ 7 p.m., Central time, or by email to transplant@humana.com.
    ACDs for medications on the list can be initiated by submitting a fax or phone request as described in the prior authorization instructions.
    PurposeUse an ACD when a service is investigational/experimental or coverage is uncertain to confirm payment before providing the service.
    ‡ (HCPCS/NOC NDC requirement) — explanation
    Meaning of '‡'Drugs or entries marked with '‡' indicate that all shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding NDC to be billed on claims.
    Where shownThe '‡' annotation appears beside listed medications where HCPCS or NOC codes are shared across products (see multiple list entries).
    ActionWhen you see '‡' on the drug list, include the appropriate NDC on the claim to identify the exact product supplied.
    ** (Step therapy) — legend
    Meaning of '**'Drugs marked with '**' require step therapy through a Humana‑preferred drug as part of the preauthorization process.
    ImplicationPrior authorization for a '**' drug may require documentation of trial and failure (or contraindication) of the preferred agent(s).
    ReferenceSee Humana's Medicare Part B Step Therapy Preferred Drug List (PDL) for details on preferred and nonpreferred medications and step requirements.
    †† (Transplant review) — legend and submission route
    Meaning of '††'Entries marked '††' indicate preauthorization requests will be reviewed by the Humana National Transplant Network.
    Submission routesTransplant-related preauthorization requests must be submitted by fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. CT), or by email to transplant@humana.com.
    ScopeApplies to transplant-related drugs listed with the '††' annotation on the prior authorization list.
    HCPCS/NOC codes requiring a corresponding NDC on claims — examples
    ClassificationHCPCS codes that are shared or coded as 'not otherwise classified' (e.g., C9399, J3490, J9999) on the drug list require a corresponding NDC on claims.
    Examples from listAmntagvi (lifileucel) maps to C9399, J3490, J9999; Rybrevant Faspro maps to C9399, J3490, J3590, J9999 — these entries illustrate where an NDC is required with the shared/NOC code.
    Billing instructionInclude the specific product NDC when submitting claims that use these shared or NOC HCPCS codes to correctly identify the drug provided.